Tissue Therapies (TIS) Another Biotech

[tommy]

Tissue Therapies (TIS) is a biotechnology company with exclusive international rights in wound healing and tissue regeneration. TISs technology VitroGro is a biological formulation for enhancing cell growth and migration developed at the Queensland University of Technology.

www.tissuetherapies.com

I don't hold Tissue Therapies (TIS) but have been keeping an eye on it since last year and recently they made a breakthrough in their research.

As with all other biotechs, it's still in its infancy, high risk and might take a while for them to turn cash-flow positive but one announcement with a major pharma for commercialization can send this puppy to the roof considering the nature of their latest research success.
May be worth keeping an eye on for biotech believers.

http://sa.iguana2.com/cache/47292542...TIS-177327.pdf

ASX ANNOUNCEMENT
30 May 2006
VitroGro World-First: Culture of Human Embryonic Stem Cells for Therapeutic Use

Breakthrough research at QUT has found that Tissue Therapies Limited�fs (ASX: TIS) VitroGro#174; technology can be used to replace animal or human serum in the culture of human embryonic stem cells, the Company announced today.

Tissue Therapies CEO Dr Steven Mercer said the VitroGro#174; breakthrough was a world-first and a significant milestone in the race to use human embryonic stem cells for medical treatments.

He said the application of the VitroGro#174; technology to stem cell sciences potentially removed one of the most significant obstacles to approved use of stem cell therapies.

�gTraditional culture of human embryonic stem cells requires the presence of animal- or humanderived serum in the growth media for the embryonic stem cells to survive and grow,�h he said. �gHealth regulators such as the American Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) have always held serious concerns about the possible transmission of infections to humans treated with stem cells grown in the presence of serum.
�gUntil now, there have been no practical alternatives to serum for the growth of human embryonic stem cells and this has been a major impediment to the approval of stem cell therapies for human
treatment.

�gThe QUT research has proven that the presence of Tissue Therapies�f VitroGro#174; allows human embryonic stem cells to be grown through more than 20 generations without serum, and the cells still retain characteristics indicating that they have maintained their original potential to form a range of human tissues.�h

The research was conducted by QUT doctoral candidate Sean Richards, under the leadership of Professor Zee Upton, one of the original inventors of the VitroGro#174; technology platform.

Prof Upton said the research proved that human embryonic stem cells can be successfully grown and expanded using Tissue Therapies�f VitroGro#174;, thereby eliminating the need for human or animal serum in the cell culture media.

�gThis is a unique and exciting discovery with huge implications for scientific and medical research and ultimately, therapeutic uses of human embryonic stem cells,�h she said.

Dr Mercer said the discovery had significant potential to accelerate the practical application of human stem cell therapies to develop cures for a wide range of devastating diseases.

�gThe eradication of animal or human serum from the stem cell culture process removes one of the most serious and difficult heath regulatory objections to the use of stem cell therapies in humans,�hhe said.

�gTissue Therapies is currently in negotiations with a number of large international companies who supply cell culture products or use various types of human stem cells.

�gWe will be working with them to translate this into practical clinical outcomes for patients, as well as commercial returns for Tissue Therapies shareholders.

�gThis research validates and demonstrates the versatility and power of the VitroGro#174; technology. �gWe expect to confirm additional clinical applications of the Vit

[lewinsky]

And now for a change from gold and silver.
No posts on this from the original post in 2006.

It is worth reading a couple of their presentations. They are making good progress and have cash in hand.

Burn rate is $170k a month.


A very substantial rise over the last few weeks.

Could be worth putting on the radar.

I will be doing more research.

[Jaa]

I have held this one for 6 months or so since their SPP.

The product itself looks like a major step forward for medical science but we will have to see if it delivers on its promise. So far the science is holding up well in the real world and the management seem competent.

Everything now rests on one trial they are doing in the UK with their new formula. They seem very confident that the results will be similar to the excellent results from their first two trials with the old formula.

They have also hired a commercialisation consultant to help in negotiations with 6 different large pharma companies.

Share price looks a bit overcooked at the moment to me but what do I know!

[Jaa]

Up 20% yesterday in a belated reaction to a market update, which said the key trial has been delayed to early next month and that they are making excellent progress with the potential commerical partners.

A few other points:

- A commercial agreement is not dependent on the UK trial results and may come first.
- The commerical partner will help with FDA approval in the US.

Just words for sure but the sell side evaporated!

[yogi-in-oz]

Hi folks,

TIS ... has had a strong upmove, since early September 2010,
though volumes during this time have been very moderate,
but this is not unusual, as many biotechs have been
in overlooked our market.

Over the past week or so, the price action has formed a
pennant, finishing with a doji (indecision), last Friday.

Our astroanalysis for TIS this week will have us alert for
a positive cycle to bring some news, around 11-12012011.

have a great day

paul



=====

[Taijon]

Anyone holding this stock now? I don't hold but I have looked at it on and off for years now. At the AGM yesterday the CEO announced partnering arrangements in Europe but there don't appear to be any financial details. Perhaps this was a disappointment as shareholders seem to be bailing out large - down 17% today on top of a fall yesterday. Anyone got any thoughts?